These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22218453)

  • 41. Biosimilars: are they ready for primetime in the United States?
    Hirsch BR; Lyman GH
    J Natl Compr Canc Netw; 2011 Aug; 9(8):934-42; quiz 943. PubMed ID: 21900222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biosimilars and the efficiency principle].
    Münnch T
    Z Gastroenterol; 2016 Nov; 54(11):1230-1232. PubMed ID: 27723913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.
    Inotai A; Csanadi M; Petrova G; Dimitrova M; Bochenek T; Tesar T; York K; Fuksa L; Kostyuk A; Lorenzovici L; Omelyanovskiy V; Egyed K; Kalo Z
    Biomed Res Int; 2018; 2018():9597362. PubMed ID: 29546072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
    Lakhanpal A; Brahn E
    Clin Rheumatol; 2016 Dec; 35(12):2869-2875. PubMed ID: 27714482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
    Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
    Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 50. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biological agents and biosimilars: Essential information for the internist.
    Pasina L; Casadei G; Nobili A
    Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biosimilars: Exploring the History, Science, and Progress.
    Tariman JD
    Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.